P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

Y. Zhu; Y. Chen; S. Han; X. Ying; X. Sun; Y. Xu

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

【24h】

P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

机译：P1.01-100同期脑放射治疗和EGFR-TKI在EGFR-突变体NSCLC脑转移患者中具有更好的生存益处

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
Y. Zhu; Y. Chen; S. Han; X. Ying; X. Sun; Y. Xu;
展开▼
作者单位

Shanghai Pulmonary Hospital;

Shanghai Pulmonary Hospital;

Zhejiang Cancer Hospital;

Lishui Central Hospital of Zhejiang;

Zhejiang Cancer Hospital;

Shanghai Pulmonary Hospital;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC [J] . Y. Zhu, Y. Chen, S. Han, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P1.01-100同期脑放射治疗和EGFR-TKI在EGFR-突变体NSCLC脑转移患者中具有更好的生存益处
2. MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis [J] . X. Xia, M. Guo, J. He, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：MA08.03 EGFR-TKI加脑放射疗法与EGFR-TKI单独在EGFR突变的NSCLC患者中脑转移的患者中：META分析
3. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J] . Ballard Peter, Yates James W. T., Yang Zhenfan, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第20期

机译：奥西替尼与其他EGFR突变型NSCLC脑转移模型的临床前比较，以及临床脑转移活性的早期证据
4. Identification of Rules for Brain Metastases and Survival Time Prediction for Small Cell Lung Cancer Patients [C] . Kwei Aryeetey, Wojciech Ziarko, Patricia Tai, International Symposium on "Intelligent Information Systems X", Jun 18-22, 2001, Zakopane, Poland . 2001

机译：小细胞肺癌患者脑转移和生存时间预测规则的确定
5. Use of Palliative Radiotherapy Among Metastatic Non-small-cell Lung Cancer (NSCLC) Patients in Puerto Rico [D] . ?Quinones Avila, Valerie 2020

机译：在波多黎各的转移性非小细胞肺癌（NSCLC）患者中使用姑息放射治疗
6. Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score [O] . Yongmei Liu, Lei Deng, Xiaojuan Zhou, 2017

机译：并行脑放疗和EGFR-TKI可以改善非小细胞肺癌的颅内转移控制并且对DS-GPA评分低的患者具有生存益处
7. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [O] . Peter Ballard, James W.T. Yates, Zhenfan Yang, 2016

机译：Esimertinib与其他EGFR-TKIS在EGFR-突变体NSCLC脑转移模型中的临床前比较，以及临床脑转移活动的早期证据
8. Dual Benefit of TGFB Inhibition on Tumor Control in the Context of Radiotherapy for Breast Cancer Brain Metastases. [R] . Barcellos-Hoff, M. 2018

机译：TGFB抑制乳腺癌脑转移瘤放射治疗中肿瘤控制的双重效益。

P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

著录项

相似文献

相关主题

期刊订阅